Stocks · Health care · Pharmaceutical Preparations

Altimmune, Inc.

ALT Clue Score41
United States Fiscal year ends December CIK 0001326190 Results filed 12 Aug 2026

What the insiders did Net buying

By person

12 insiders · 11 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Jerome Benedict Durso
President and CEO
$213.71K (4)
—
+$213.71K
62,500
$184.38K
—
John Gill
Director
$82.60K (2)
—
+$82.60K
21,700
$64.02K
—
Gregory L Weaver
Chief Financial Officer
$49.20K (2)
—
+$49.20K
49,927
$147.28K
—
Wayne Pisano
Director
$20.41K (1)
—
+$20.41K
13,498
$39.82K
+58.8%
Catherine A. Sohn
Director
$2.12K (1)
—
+$2.12K
1,500
$4.43K
—
Diane Jorkasky
Director
$2.00K (1)
—
+$2.00K
527
$1.55K
—
Vipin K Garg
Director
—
—
—
424,519
$1.25M
+45.4%
M Scot Roberts
Chief Scientific Officer
—
—
—
113,699
$335.41K
+162.5%
Raymond M Jordt
Chief Business Officer
—
—
—
70,107
$206.82K
+378.2%
Christophe Arbet-Engels
Chief Medical Officer
—
—
—
24,821
$73.22K
—
Linda M Richardson
Chief Commercial Officer
—
—
—
17,174
$50.66K
—
Matthew Scott Harris
Chief Medical Officer
—
—
—
16,087
$47.46K
−70.8%

No percentages here. This company's share count has moved by a factor of 2.5 over the window, from 77,013,658 to 194,517,701 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.